Stiff Person Syndrome (SPS)
Based on the clinical symptoms described, the patient has Stiff Person Syndrome (SPS), and treatment should consist of benzodiazepines (diazepam as first-line), baclofen, and intravenous immunoglobulin (IVIg), with early initiation being critical to prevent respiratory failure and sudden death 1, 2.
Clinical Presentation
SPS is an extremely rare autoimmune disorder characterized by:
- Progressive muscle rigidity and stiffness, typically starting in axial and limb muscles
- Episodic painful muscle spasms triggered by stimuli
- Gait abnormalities and eventual inability to walk
- Continuous contraction of agonist and antagonist muscles
- Life-threatening respiratory complications including recurrent respiratory failure requiring mechanical ventilation 1, 2
The hallmark electrophysiological finding is continuous motor-unit firing at rest, though neurologic examination is otherwise typically normal 3.
Diagnostic Confirmation
The diagnosis requires:
- Elevated anti-glutamic acid decarboxylase (anti-GAD65) antibodies in serum - found in high titers in most patients 2, 3
- Electromyography showing continuous motor unit activity
- Rule out other conditions through normal brain imaging (CT/MRI) 3
Critical pitfall: In patients with respiratory failure requiring ICU admission, critical illness polyneuropathy (CIP) can coexist with SPS, showing low/absent compound muscle action potentials and sensory nerve action potentials on EMG, which can complicate diagnosis 2.
Treatment Algorithm
Immediate Symptomatic Control
Diazepam - first-line agent that enhances GABA neurotransmission
Baclofen (5 mg twice daily, titrate as needed)
Clonazepam (0.5 mg twice daily) - alternative benzodiazepine option 2
Immunomodulatory Therapy
Intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 days offers substantial improvement and should be initiated promptly 2, 3. This addresses the underlying autoimmune pathogenesis where anti-GAD antibodies interfere with GABA synthesis.
Alternative immunomodulatory options include:
- Corticosteroids
- Plasmapheresis 3
Respiratory Management
Given the 9-year history of recurrent respiratory failure episodes in documented cases 1:
- Monitor respiratory function closely - approximately 20% of patients can develop respiratory failure
- Early tracheostomy may be necessary in severe cases with recurrent episodes 1
- ICU admission for acute respiratory decompensation
Pathophysiology Context
The syndrome results from antibodies against GAD65 (the enzyme synthesizing GABA), leading to reduced GABA levels particularly in the motor cortex 3. This explains why GABA-enhancing medications are the cornerstone of symptomatic treatment, while immunotherapy addresses the autoimmune root cause.
The evidence strongly supports that regular administration of the three-drug combination (benzodiazepine + baclofen + IVIg) not only controls symptoms and disease progression but critically prevents further respiratory failure and possible sudden death 1. Delayed or irregular treatment increases mortality risk in this already rare condition with significant morbidity.